Immunogenicity, Reactogenicity and Safety of GSK Biologicals' Quadrivalent Influenza Vaccine FLU Q-QIV (GSK2282512A) When Administered Intramuscularly to Adults 18 Years of Age and Older.

Trial Profile

Immunogenicity, Reactogenicity and Safety of GSK Biologicals' Quadrivalent Influenza Vaccine FLU Q-QIV (GSK2282512A) When Administered Intramuscularly to Adults 18 Years of Age and Older.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Oct 2016

At a glance

  • Drugs GSK 2282512A (Primary) ; GSK 1536489A
  • Indications Influenza A virus infections; Influenza B virus infections
  • Focus Pharmacodynamics; Registrational
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 28 Jan 2014 Results published in the Vaccine.
    • 28 Nov 2012 Primary endpoint 'Immunological-response-rate' has been met.
    • 28 Nov 2012 Primary endpoint 'Antibody-levels' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top